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ABSTRACT: The malaria parasite Plasmodium falciparum (Pf)
changes the structure and mechanical properties of red blood cells
(RBCs). These changes decrease deformability and increase
cytoadherence of Pf-infected RBCs to the vascular endothelium,
eventually leading to ﬂow occlusions in capillary vessels. In this
study, to detect Pf-infected RBCs eﬀectively, deformability and
viscosity of blood sample are measured simultaneously and
indirectly by quantifying blood ﬂow in a microﬂuidic device. The
microﬂuidic device is designed by mimicking a Wheatstone-bridge
electric circuit. To measure RBC deformability, a deformability
assessment chamber (DAC) at the left lower side channel has
parallel microﬂuidic ﬁlters. After delivering blood sample and 1×
PBS solution at the same ﬂow rate, hemodynamic properties are
measured using a time-resolved microparticle image velocimetry technique. Blood volume delivered into the DAC for 200 s is
evaluated as a deformability index. Subsequently, blood viscosity is quantiﬁed by monitoring blood-ﬁlled width of parallel ﬂows in
the microﬂuidic device. The proposed method is applied to evaluate variations in biophysical properties of blood samples
partially mixed with normal RBCs and hardened RBCs. As a result, RBC deformability is more eﬀective than blood viscosity in
the detection of blood samples with hardened RBC volume fraction of 5%. The microﬂuidic device is also applied to detect Pf-
infected RBCs. When parasitemia is greater than 0.515% for ring stage, 0.0544% for trophozoite stage, and 0.0054% for schizont
stage, the measured velocity ﬁelds show unstable behavior because of cytoadherence of Pf-infected RBCs. Blood volume
delivered into the DAC signiﬁcantly decreases with increasing parasitemia. The experimental method proposed in this study can
detect Pf-infected RBCs with good accuracy.
Among various biophysical properties of blood, red bloodcell (RBC) deformability has been considered a potential
biomarker for monitoring pathological changes related to
various hematologic diseases.1 RBC deformability depends on
several factors, including membrane cytoskeleton, membrane
integral proteins, cytoplasmic viscosity, and surface−volume
ratio. It largely decreases under hematologic disorders,
including malaria, sickle cell anemia, sepsis, spherocytosis, and
diabetes.2
The malaria parasite Plasmodium falciparum (Pf) changes the
structure and mechanical properties of RBCs when the parasite
progresses from ring stage to schizont. These changes
substantially decrease deformability and increase cytoadherence
of Pf-infected RBCs to the vascular endothelium, eventually
leading to ﬂow occlusions of capillary vessels.3,4 Microscopic
examination of Giemsa-stained blood smear has been used as a
standard method to diagnose malaria. Although this technique
can identify parasitemia as low as 0.001%,5 it has several
disadvantages, such as extremely low throughput, tedious
operation procedure, and limited availability of experienced
experts. Recently, various microﬂuidic devices have been
suggested as an ideal platform to detect Pf-infected RBCs
eﬀectively.
As changes in hemorheological or hemodynamic properties
are strongly related to hematological diseases, various blood
biophysical properties, including viscosity, erythrocyte sed-
imentation rate,6 and deformability, have been used to detect
Pf-infected RBCs. Several experimental techniques that utilize
multiple physical principles, including hydrodynamics, optics,
and electromagnetics, have been proposed to diagnose Pf-
infected RBCs. First, morphological deformation of a single
RBC that passes through a straight or constricted microﬂuidic
channel is carefully monitored. Various biophysical properties,
such as minimum cylinder diameter,7 transit time,8 occlusion,9
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RBC velocity,10 lateral migration,11 cortical tension,12 electrical
impedance,13 and cytoadherence,14 for individual Pf-infected
RBCs exhibit diﬀerent values, compared with those for normal
RBCs. Second, under quasi-static ﬂow conditions, morpho-
logical properties, such as membrane ﬂuctuations15 and optical
stretcher-based elasticity,16 are used to quantify Pf-infected
RBCs. Finally, hemozoin, which is converted from hemoglobin
during parasite progression, shows variation of magnetic
characteristics.17 Its lateral migration is evaluated to detect Pf-
infected RBCs under a magnetic ﬁeld. Most of these previous
methods have been employed to detect individual Pf-infected
RBCs by measuring RBC deformability. However, RBC
deformability changes under various pathological conditions.
Therefore, additional quantiﬁcation of biophysical properties of
a blood sample is required to detect Pf-infected RBCs
eﬀectively. In addition, these single RBC-based diagnostic
methods have limitations in practical applications, especially
from extremely low throughput. Thus, a new microﬂuidic-based
method that can provide high throughput is necessary.
In this study, a simple, high-throughput, and label-free
measurement technique is proposed to detect Pf-infected RBCs
through quantitative measurement of hemodynamic variations
in a microﬂuidic analogue of a Wheatstone-bridge electric
circuit. The microﬂuidic device has two inlets and outlets, as
well as a typical H-shaped channel with a deformability
assessment chamber (DAC). The DAC is composed of parallel
microﬂuidic ﬁlters with a microsized gap. After injecting blood
sample and reference ﬂuid into each inlet of the microﬂuidic
device, hemodynamic variations in the microﬂuidic channels are
measured using a time-resolved microparticle image velocim-
etry (PIV) technique. First, the deformability of blood samples
is evaluated by analyzing blood ﬂow in the DAC for a certain
period. The deformability of blood samples can be measured
with high throughput and subpopulation measurement
Figure 1. Schematics of the proposed method for simultaneous measurement of the deformability and viscosity of blood samples by monitoring
hemodynamic variations in the microﬂuidic device. (A) Schematic of the experimental setup, including two syringe pumps for delivering the blood
sample and reference ﬂuid, and a disposable microﬂuidic device for measuring deformability and viscosity of the blood sample. The microﬂuidic
device is conceptually mimicked from a Wheatstone-bridge electric circuit. It consists of two inlets and outlets, two identical upper channels, two
lower side channels, and one bridge channel (BRG). The left lower side channel has a deformability assessment chamber (DAC) with parallel
microﬂuidic ﬁlters (gap = 2 μm, depth = 4 μm, length = LDAC, and N = 43), which is specially devised to measure RBC deformability. (B) The
working principle for measuring the deformability and viscosity of blood samples. When blood sample and reference ﬂuid are supplied into each
inlet, all channels except the right upper side channel are ﬁlled with blood sample. After a certain period from (a) T = t1 to (b) T = t2, the
microﬂuidic ﬁlters in the DAC are partially clogged because of RBC deformability. At (c) T = t3, most of the microﬂuidic ﬁlters are clogged. (d) At T
> t3, the blood sample and reference ﬂuid are supplied into the right lower side channel. The blood-ﬁlled width (αBlood) varies depending on viscosity
ratio (μBlood/μRef) and ﬂow-rate ratio (QBlood/QRef). (C) Average velocities of blood ﬂow in the DAC (<U>DAC) and bridge channel (<U>BRG) are
evaluated using a time-resolved micro-PIV technique. At intervals of 0.5 s, two microscopic images are consecutively captured with a high-speed
camera at a frame rate of 5 kHz. (D) For a preliminary demonstration, blood sample (Hct = 50%) is prepared by adding normal RBCs into 1× PBS
solution. In this study, 1× PBS solution is used as the reference ﬂuid. Snapshots are captured at diﬀerent time points (t) [(a) t = 0 s, (b) t = 20 s, (c)
t = 100 s, and (d) t = 200 s]. By conducting a time-resolved micro-PIV technique and digital image processing, the average velocities of blood ﬂow in
the DAC and bridge channel (<U>DAC, <U>BRG) and blood-ﬁlled width (αBlood) are obtained as a function of time. <U>DAC gradually decreases
because of consecutive clogging of RBCs in the microﬂuidic ﬁlters. RBC deformability is quantiﬁed by integrating the ﬂow rate in the DAC for 200 s.
After 200 s, the viscosity of blood sample is evaluated by monitoring the blood-ﬁlled width (αBlood), which remains constant.
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accuracy. Using the parallel ﬂow formed by the two ﬂuids on
the right lower side channel of the microﬂuidic device, the
viscosity ratio of blood sample to the reference ﬂuid is
measured by monitoring the blood-ﬁlled width and using
hydrodynamic force balance in the channel. Thus, both
deformability and blood-ﬁlled width in parallel ﬂow are used
to detect Pf-infected RBCs via a label-free and high-throughput
technique.
Compared with previous measurement techniques, the
proposed method has distinct advantages. First, the proposed
method can evaluate the RBC deformability of a small amount
of blood sample (∼0.2 mL) with a high hematocrit (∼50%),
especially within a short time period (∼5 min). Second, it can
detect small variations in RBC deformability caused by
subpopulations in heterogeneous blood sample with high
sensitivity. Third, the proposed method can measure blood
viscosity as a hemorheological property that depends on several
factors, including hematocrit, deformability, aggregation, and
base solution. Finally, this technique can quantitatively evaluate
the cytoadherence of Pf-infected RBCs by measuring the
temporal variations in velocity ﬁelds of the ﬂow of the blood
sample passing through the microﬂuidic channel.
The performance of the proposed method is quantitatively
evaluated by varying four factors, namely, the size of
microﬂuidic ﬁlter in the DAC, ﬂow rate and hematocrit of
the blood sample, and base solution. Thereafter, as a
preliminary demonstration for the diagnosis of malaria-infected
blood sample with low parasitemia, human blood samples that
are partially mixed with normal RBCs and hardened RBCs are
tested to quantitatively evaluate variations in RBC deformability
caused by small diﬀerences in subpopulations. In addition,
change of blood ﬂow due to enhanced RBC aggregation is
evaluated. Finally, as a clinical application, the proposed
method is applied to detect Pf-infected RBCs.
■ EXPERIMENTAL SECTION
Simultaneous Measurement of Deformability and
Viscosity of Blood Samples. A simple, label-free, and high-
throughput measurement technique is proposed to detect Pf-
infected RBCs. This method can measure the deformability and
viscosity of blood samples by monitoring hemodynamic
variations in a microﬂuidic analogue of a Wheatstone-bridge
electric circuit. In addition, the proposed method can precisely
detect small diﬀerences in subpopulations by measuring
velocity ﬁelds of blood ﬂow in the microﬂuidic channel.
The experimental setup is composed of two syringe pumps, a
microﬂuidic device for measuring deformability and viscosity of
blood sample, and an image acquisition system composed of a
microscope and high-speed camera. As shown in Figure 1A, the
microﬂuidic device is conceptually mimicked from a Wheat-
stone-bridge electric circuit. The device consists of two inlets
and outlets, two identical upper channels, a left lower side
channel with a DAC, right lower side channel, and one bridge
channel (BRG). The DAC has parallel microﬂuidic ﬁlters
(width = 2 μm, depth = 4 μm, length = LDAC, and N = 43).
Each disposable syringe is ﬁlled with an equal volume (∼0.2
mL) of blood sample and reference ﬂuid. After installing the
two syringes into each syringe pump, the blood sample (i.e.,
Blood) and reference ﬂuid (i.e., Ref) are supplied into the
microﬂuidic device at a ﬁxed ﬂow rate of 1 mL/h (QBlood = QRef
= 1 mL/h).
As shown in Figure 1B, the deformability and viscosity of
blood sample are sequentially measured by monitoring
hemodynamic variations in the DAC and right lower side
channel. Two ﬂuids are supplied into the microﬂuidic device at
the same ﬂow rate (QBlood = QRef). Therefore, all channels
except the right upper side channel are ﬁlled with blood sample
because the viscosity of blood sample is greater than that of the
reference ﬂuid, and the overall ﬂuidic resistance in the DAC is
much greater than that in the right lower side channel. Instead,
the upper right side channel is only ﬁlled with the reference
ﬂuid.
At T = t1, all microﬂuidic ﬁlters in the DAC are completely
ﬁlled with the blood sample as shown in Figure 1B-(a). After a
certain time is elapsed from T = t1 [Figure 1B-(a)] to T = t2
[Figure 1B-(b)], the microﬂuidic ﬁlters in the DAC are partially
clogged because of RBC deformability, which hinders blood
ﬂow in the DAC. At T = t3 [Figure 1B-(c)], the microﬂuidic
ﬁlters in the DAC are completely clogged. Blood ﬂow in the
DAC is totally interrupted. Moreover, the lower regions of the
DAC are only ﬁlled with base solution of the blood sample.
Thereafter, at T > t3 [Figure 1B-(d)], blood sample and
reference ﬂuid are separated, and formed as parallel ﬂows into
the right lower side channel. Using a discrete parameter model,
the ﬂuidic circuit is simply modeled with ﬂow rate (QBlood, QRef)
and ﬂuidic resistance (RBlood, RRef). For a rectangular channel
(w = width, h = depth) with an extremely low aspect ratio (i.e.,
h/w = 4/250), ﬂuidic resistance (Rf) is approximately derived as
Rf = 12μL/(wh
3). Since depth (h) and length (L) of the
microﬂuidic channel are the same for both ﬂuids, ﬂuidic
resistance ratio (i.e., RBlood/RRef) is mathematically derived as
RBlood/RRef = (μBlood/μRef)·(1 − αBlood)/αBlood. Here, μBlood and
μRef represent the viscosities of blood sample and reference
ﬂuid, respectively. In addition, taking into account the fact that
each ﬂuid has the same pressure drop in the channel (i.e., ΔP =
RBlood·QBlood = RRef·Qref), viscosity ratio (i.e., μBlood/μRef) is
simply derived as eq 1
μ
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This equation indicates that the blood-ﬁlled width (αBlood)
varies depending on the viscosity ratio (μBlood/μRef) at the same
ﬂow rate condition (i.e., QBlood = QRef).
Flow rates in the DAC (QDAC) and bridge channel (QBRG)
are needed to measure the deformability and viscosity of the
blood sample. As shown in Figure 1C, velocity ﬁelds of the
blood sample in the DAC and bridge channel are measured
using a time-resolved micro-PIV technique. Average velocities
of the blood sample in the DAC (<U>DAC) and bridge channel
(<U>BRG) are calculated using the arithmetic average method.
As the blood sample is constantly supplied at a ﬂow rate of
QBlood, and average velocities in the DAC and bridge channel
are estimated with respect to time, two ﬂow rates (QDAC and
QBRG) are mathematically evaluated as eqs 2 and 3
= ⟨ ⟩
⟨ ⟩ + ⟨ ⟩
Q
U
U U
QDAC
DAC
DAC BRG
Blood
(2)
= ⟨ ⟩
⟨ ⟩ + ⟨ ⟩
Q
U
U U
QBRG
BRG
DAC BRG
Blood
(3)
In eq 3, when <U>DAC ≈ 0, QBRG is equal to QBlood. Thus, all
blood samples pass through the bridge channel without any
loss, as shown in Figure 1B-(d).
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For a preliminary demonstration, a blood sample with a
hematocrit of Hct = 50% is prepared by adding normal RBCs
into 1× PBS solution. In addition, 1× PBS solution is used as
the reference ﬂuid. As shown in Figure 1D, microscopic images
are consecutively captured at diﬀerent lapses of time (t) [(a) t =
5 s, (b) t = 40 s, (c) t = 100 s, (d) t = 200 s]. By conducting the
time-resolved micro-PIV technique and digital image process-
ing, the average velocities in the DAC and bridge channel
(<U>DAC, <U>BRG) and blood-ﬁlled width (αBlood) with respect
to time are measured. From the preliminary demonstration,
<U>DAC is gradually decreased because of consecutive clogging
of RBCs in the microﬂuidic ﬁlters of the DAC. After
approximately 200 s, the blood ﬂow in the DAC is completely
stopped (i.e., <U>DAC ≈ 0). This step implies that the clogging
of RBCs in the microﬂuidic ﬁlters is closely correlated with
RBC deformability. RBC deformability can be quantiﬁed by
integrating the temporal variations in the average velocity or
ﬂow rate for a certain period. As a new deformability index, the
blood volume delivered into the DAC (ΔVDAC) is evaluated by
integrating the ﬂow rate in the DAC (QDAC) for 200 s (i.e., ts =
200 s) as eq 4
∫Δ =
=
=
V Q t t( )d
t
t t
DAC
0 DAC
s
(4)
Given that blood ﬂow in the DAC is stopped by completely
closing the outlet (A), all blood samples pass through the
bridge channel (i.e., QBRG = QBlood). Using parallel ﬂow in the
right side channel, the viscosity variation of blood sample is
evaluated by monitoring the blood-ﬁlled width (αBlood).
Furthermore, to quantify the variation of blood ﬂow due to
cytoadherence of RBCs in the microﬂuidic channel, the blood
volume delivered into the bridge channel (ΔVBRG) is evaluated
by integrating the ﬂow rate in the bridge (QBRG) for 100 s using
eq 5,
∫Δ =
=
= +
V Q t t( )d
t t
t t
BRG
100 s
BRG
0
0
(5)
Here, t0 is greater than 200 s (i.e., t0 > 200 s).
Fabrication of the Microﬂuidic Device and Exper-
imental Procedure. The microﬂuidic device, which mimics a
Wheatstone-bridge electric circuit, consists of two inlets, two
outlets, and two parallel side channels. A bridge channel (length
= 1500 μm, width = 250 μm) is connected to both side
channels. The upper side channels have identical dimensions
(length = 7300 μm, width = 250 μm). The left lower side
channel is composed of parallel microﬂuidic ﬁlters (N = 43, gap
= 2 μm, overall length = 400 μm) in the DAC. The lower right
side channel is 7300 μm in length and 250 μm in width. The
depth of the microﬂuidic channels is ﬁxed at 4 μm.
A silicon-master molder is fabricated using microelectrome-
chanical system fabrication techniques, including photolithog-
raphy and deep reactive ion etching. Thereafter, polydime-
thylsiloxane (PDMS) (Sylgard 184, Dow Corning, Midland,
MI, U.S.A.) is mixed at a 1:10 ratio of curing agent to PDMS
monomer. The PDMS mixture is then poured into the silicon-
master molder placed in a Petri dish. Air bubbles dissolved in
PDMS are suﬃciently removed using a vacuum pump. After
curing PDMS in a convection oven at 80 °C for 2 h, the PDMS
sheet is peeled oﬀ from the silicon-master molder. A PDMS
block is cut from the PDMS sheet with a razor blade. Two
inlets and two outlets of the PDMS block are punched with a
biopsy punch (O.D. = 1 mm). After treating the PDMS block
and a glass slide with oxygen plasma, a microﬂuidic device is
fabricated by bonding the PDMS block to the glass slide.
The microﬂuidic device is then placed on an optical
microscope (Nikon, Tokyo, Japan) attached with a 4×
objective lens (NA = 0.1). Two disposable syringes (1 mL,
BD Biosciences, Singapore) are ﬁlled with 1% bovine serum
albumin (BSA) solution. Each disposable syringe is connected
to the two inlets with a polyethylene tube (I.D. = 250 μm,
length = 300 mm). In addition, two polyethylene tubes (I.D. =
250 μm, length = 100 mm) are connected to the two outlets.
After installing two disposable syringes into a syringe pump
(neMESYS, centoni GmbH, Germany), 1% BSA solution is
delivered into the microﬂuidic device at a ﬂow rate of 1 mL/h
for 5 min. Air bubbles in the microﬂuidic device are completely
removed. Thereafter, the two disposable syringes are ﬁlled with
the blood sample (VBlood = 0.2 mL) and 1× PBS solution (VRef
= 0.2 mL). After installing two syringes into the syringe pumps,
both ﬂuids are delivered into the microﬂuidic device at the
same ﬂow rate of 1 mL/h (i.e., QBlood = QRef = 1 mL/h). All
experiments are conducted at room temperature (25 °C).
Time-Resolved Micro-PIV Technique and Digital
Image Processing. A high-speed camera (FASTCAM SA
1.1, Photron, San Diego, CA, U.S.A.) is employed to capture
images of blood ﬂow in the microﬂuidic channel. The camera
has a spatial resolution of 1280 × 1024 pixels, with each pixel
corresponding to 10 μm. For long-term measurement of 5 min,
the high-speed camera is synchronized using a digital delay
pulse generator (Model 555, BNC, San Rafael, CA, U.S.A.).
After setting the frame rate of the high-speed camera at 5 kHz,
two consecutive images are sequentially captured at intervals of
0.5 s. To evaluate the temporal hemodynamic variations in the
DAC and bridge channel, velocity ﬁelds of blood ﬂow in the
DAC and bridge channel are quantiﬁed by conducting a time-
resolved digital micro-PIV technique. Two speciﬁc regions of
interest (ROIs) measuring 50 × 60 pixels in the DAC and
bridge channel are selected to obtain velocity ﬁelds of blood
ﬂow. The interrogation window size is 8 × 8 pixels, and window
overlap is 50%. The obtained velocity vectors are validated with
a median ﬁlter. By obtaining the arithmetic average of
instantaneous two velocity ﬁelds, the average velocities in the
DAC and BRG (<U>DAC, <U>BRG) with respect to time are
obtained. In addition, a speciﬁc ROI (50 × 50 pixels) in the
lower right side channel is carefully selected to evaluate the
blood-ﬁlled width (αBlood). Using a commercial software
(Matlab, Mathworks, U.S.A.), temporal variations in the
blood-ﬁlled width (αBlood) in the right lower side channel are
quantitatively evaluated from the images captured consecutively
by the high-speed camera. An adaptive equal histogram method
is used to enhance image contrast of the captured images. To
obtain the interfacial position between the blood sample and
reference ﬂuid along the microﬂuidic channel, the captured
images are converted into binary images by adopting Otsu’s
method. After obtaining the arithmetic average of pixel values
in the ROI for each image, the blood-ﬁlled width (αBlood) with
respect to time is obtained.
Sample Preparation of Normal Blood and Malaria-
Infected Blood. The human RBCs and plasma tested in this
study are provided by Daegu−Gyeongbuk Blood Bank
(Gyeongbuk, South Korea). The hematocrit of the blood
samples is adjusted to 30%, 40%, and 50% by carefully adding
normal RBCs into base solution [1× PBS solution (pH 7.4, Bio
Solution, Seoul, South Korea), plasma]. To decrease the
deformability of normal RBCs, normal RBCs are dipped into
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various concentration of glutaraldehyde solution (CGA) (Junsei
Chemical Co., Tokyo, Japan), which ranges from CGA = 0.0% to
CGA = 0.25% for 10 min. The hematocrit of the hardened blood
sample is adjusted to 50% by adding hardened RBCs into 1×
PBS solution. The hematocrit of normal blood is also set to
50% by adding normal RBCs into 1× PBS solution.
Heterogeneous blood samples with a hardened blood volume
fraction (ψ) [(a) ψ = 0%, (b) ψ = 2%, (c) ψ = 5%, (d) ψ =
10%] are prepared by mixing hardened blood sample with
normal blood sample. The hardened RBCs were prepared with
GA solution of 0.25%. In this study, ψ = 0% represents the
normal blood sample.
Pf (isolate 3D7) is maintained in an incubator containing
human RBCs (blood type O+), RPMI 1640 (buﬀered with 25
mM HEPES and 25 mM NaHCO3), 10 μg/mL gentamycin,
and 370 μM hypoxanthine under a gas mixture (5% CO2, 5%
O2, and 90% N2) at 37 °C. The parasites are diluted using a
culture medium containing normal RBCs to prepare blood
samples with 5% hematocrit and maintain the parasitemia (P)
[(a) P = 0.0004%, (b) P = 0.0045%, (c) P = 0.0458%, and (d) P
= 0.458%]. The hematocrit of the Pf-infected blood sample is
set to 50% by adjusting with 1× PBS solution. In addition, to
visualize the cytoadherence of Pf-infected RBCs to the
microﬂuidic channel, a malaria-infected blood sample with
parasitemia level of 1.9% is prepared to have a hematocrit of
5%.
Giemsa Staining for Parasitemia Level Detection. A
thin blood smear is ﬁxed with 99% methanol for 5 min. After
ﬁxing a slide, the slide is dried for 1−2 min. A diluted Giemsa
stain solution (Merck, Darmstadt, Germany) is prepared prior
to staining. The slide is immersed in freshly prepared Giemsa
stain solution for 25 min, rinsed with tap water, and dried. The
stained malaria parasites are examined using a microscope
(Zeiss, Jena, Germany) with a 100× oil immersion objective
lens.
■ RESULTS AND DISCUSSION
Eﬀect of Parameters on the Delivered Blood Volume.
The blood volume delivered into the DAC (ΔVDAC) is
suggested as a deformability index to quantify the deformability
of blood samples. In addition, the viscosity ratio of blood
sample in relation to reference ﬂuid is simultaneously
monitored by detecting the blood-ﬁlled width (αBlood) in the
right lower side channel. ΔVDAC varies depending on overall
ﬂuidic resistance in the DAC, which is strongly inﬂuenced by
the ﬂuidic resistance in the parallel microﬂuidic ﬁlters. For
example, when delivering blood sample with hardened RBCs,
the RBCs are clogged or trapped in the microﬂuidic ﬁlters. This
increased ﬂuidic resistance causes to decrease the velocity of
blood ﬂow, which in turn decreases the blood volume delivered
into the DAC. In addition, the blood-ﬁlled width (αBlood) is
monitored to detect variations in blood viscosity. As shown in
Figure 2, the eﬀects of several parameters, including length of
microﬂuidic ﬁlter (LDAC), blood ﬂow rate (QBlood), hematocrit
(Hct), and base solution, especially on the variations in ΔVDAC
and αBlood are experimentally investigated.
First, to evaluate the eﬀect of the length of the microﬂuidic
ﬁlter on the variations in ΔVDAC and αBlood, the blood sample
and reference ﬂuid were simultaneously supplied into the
microﬂuidic device. The hematocrit of blood sample (normal
RBCs in PBS suspension) was ﬁxed at 50%. In addition, a
microﬂuidic device was designed to have diﬀerent lengths of the
microﬂuidic ﬁlter (LDAC) [(a) LDAC = 50 μm, (b) LDAC = 150
μm, and (c) LDAC = 250 μm]. As shown in Figure 2A, ΔVDAC
Figure 2. Quantitative evaluation on the eﬀects of four factors, namely, length of microﬂuidic ﬁlter (LDAC), blood ﬂow rate (QBlood), hematocrit
(Hct), and base solution, on the blood volume delivered into the DAC (ΔVDAC) and blood-ﬁlled width (αBlood). (A) Variations in the delivered blood
volume (ΔVDAC) and blood-ﬁlled width (αBlood) with respect to the length of the microﬂuidic ﬁlter (LDAC) [(a) LDAC = 50 μm, (b) LDAC = 150 μm,
and (c) LDAC = 250 μm]. The length of the microﬂuidic ﬁlters is ﬁxed at 250 μm (i.e., LDAC = 250 μm). (B) Variations in ΔVDAC and αBlood with
increasing ﬂow rate of blood (QBlood) [(a) QBlood = 0.5 mL/h, (b) QBlood = 1 mL/h, (c) QBlood = 1.5 mL/h, and (d) QBlood = 2 mL/h]. (C) Variations
in ΔVDAC and αBlood with respect to hematocrit (Hct) [(a) Hct = 30%, (b) Hct = 40%, and (c) Hct = 50%]. (D) Variations in ΔVDAC and αBlood for two
base solutions, such as plasma and 1× PBS solution.
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and αBlood were measured by varying the length of the
microﬂuidic ﬁlter. As a result, the blood volume delivered into
the DAC decreased with increasing length of the microﬂuidic
ﬁlter. Given that the ﬂow rate of blood in the DAC (QDAC) is
inversely proportional to the ﬂuidic resistance caused by the
microﬂuidic ﬁlter, ΔVDAC was largely inﬂuenced by the length
of the microﬂuidic ﬁlter. After closing the outlet (A), the blood-
ﬁlled width (αBlood) was also measured with varying lengths of
the microﬂuidic ﬁlter. As expected, αBlood remained constant
regardless of the length of the microﬂuidic ﬁlter. This ﬁnding
implied that the blood sample was consistently delivered into
the microﬂuidic device, and the length of the microﬂuidic ﬁlter
must be ﬁxed to eﬀectively monitor variations in ΔVDAC as a
deformability index. Thus, the length of the microﬂuidic ﬁlter
was ﬁxed at 250 μm (i.e., LDAC = 250 μm).
Second, to evaluate the eﬀect of blood ﬂow rate (QBlood) on
ΔVDAC and αBlood, the ﬂow rate of the reference ﬂuid in the
microﬂuidic device (LDAC = 250 μm) was ﬁxed at 1 mL/h (QRef
= 1 mL/h). The hematocrit of blood sample was adjusted to
50% by carefully adding normal RBCs into 1× PBS solution. As
shown in Figure 2B, ΔVDAC and αBlood were measured with
increasing blood ﬂow rate (QBlood) [(a) QBlood = 0.5 mL/h, (b)
QBlood = 1 mL/h, (c) QBlood = 1.5 mL/h, and (d) QBlood = 2
mL/h]. The results showed that ΔVDAC and αBlood signiﬁcantly
increased with increasing blood ﬂow rate. This ﬁnding
suggested that the blood ﬂow rate should be maintained
constantly for consistent measurement of ΔVDAC and αBlood.
Therefore, the ﬂow rates of the blood sample and reference
ﬂuid were maintained at the same ﬂow rate of 1 mL/h (i.e.,
QBlood = QRef = 1 mL/h).
Third, to evaluate the eﬀect of hematocrit (Hct) on ΔVDAC
and αBlood, three levels of hematocrit (Hct) [(a) Hct = 30%, (b)
Hct = 40%, and (c) Hct = 50%] were tested. The ﬂow rates of
the blood sample and reference ﬂuid delivered into the
microﬂuidic device (LDAC = 250 μm) were ﬁxed at QBlood =
QRef = 1 mL/h. The variation in ΔVDAC and αBlood with respect
to hematocrit (Hct) is shown in Figure 2C. The value of ΔVDAC
decreased up to 40% hematocrit. Thereafter, ΔVDAC did not
show signiﬁcant variation with respect to the hematocrit level.
In addition, αBlood gradually increased with increasing
Figure 3. Quantitative performance evaluation of the proposed method for homogeneous and heterogeneous blood samples. (A) Performance
evaluation for blood sample composed of homogeneous RBCs ﬁxed with various concentrations of GA solution (CGA) ranging from CGA = 0.0% to
CGA = 0.25%. (a) Variations of ΔVDAC and ΔVBRG with respect to CGA. (b) Variations of blood-ﬁlled width (αBlood) with respect to CGA. (B)
Performance evaluation for blood sample prepared by adding hardened RBCs into normal RBCs. Here, the hardened RBCs were ﬁxed only with GA
solution of 0.25% (i.e., CGA = 0.25%). (a) Temporal variations of ﬂow rate of blood sample delivered into the DAC (QDAC) with respect to volume
fraction of hardened blood (ψ). The volume fraction is deﬁned as the volume ratio of the hardened blood sample to the total blood sample. (b)
Temporal variations of blood-ﬁlled width (αBlood) for the normal blood sample (ψ = 0) and hardened blood sample (ψ = 10%). (c) Variations of
ΔVDAC and ΔVBRG with respect to ψ. (d) Variations of blood-ﬁlled width (αBlood) with respect to ψ.
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hematocrit level. This ﬁnding implied that blood viscosity
increased with increasing hematocrit level. Therefore, the
variation in hematocrit was monitored by quantifying the
blood-ﬁlled width (αBlood). On the basis of this ﬁnding, the
hematocrit level should be ﬁxed at a constant value to minimize
the eﬀect of hematocrit variation. Thus, in this study, the
hematocrit level of blood was ﬁxed at 50%.
Finally, the eﬀect of base solution on the variations in ΔVDAC
and αBlood was tested. The hematocrit levels of two diﬀerent
blood samples were adjusted to 50% by adding normal RBCs
into plasma or 1× PBS solution. The blood sample and
reference ﬂuid were supplied into the microﬂuidic device (LDAC
= 250 μm) at the same ﬂow rate of QBlood = QRef = 1 mL/h.
Variations in ΔVDAC and αBlood with respect to the base solution
are shown in Figure 2D. The results showed that ΔVDAC and
αBlood signiﬁcantly changed depending on the base solution.
Considering that the viscosity of plasma is higher than that of
1× PBS solution, ΔVDAC of plasma is lower than that of 1×
PBS solution. In addition, αBlood of plasma is much higher than
that of 1× PBS solution. Thus, blood samples were prepared
with the same base solution.
Detection of Homogeneous and Heterogeneous
Hardened RBCs. First, the performance of the proposed
method was evaluated for blood sample composed of
homogeneous hardened RBCs. The hardened RBCs were
prepared by dipping normal RBCs into various concentrations
of GA solution (CGA), which ranges from CGA = 0.0% to CGA =
0.25%. The hematocrit of the hardened blood sample was
adjusted to 50% by adding hardened RBCs into 1× PBS
solution. As shown in Figure 3A-(a), blood volume delivered
into the DAC (ΔVDAC) tends to decrease with increasing the
concentrations of GA solution. In other words, depending on
the concentration of GA solution, the normal RBCs are
gradually ﬁxed, which hinders and interrupts blood ﬂows in the
DAC. The ΔVDAC of the hardened RBCs with low
concentration of GA solution (i.e., CGA = 0.025%) is much
smaller than that of normal RBCs. This result implies that the
blood volume delivered into the DAC (i.e., ΔVDAC) can be
usefully used as a deformability index. However, the ΔVBRG
remains constant, even at high concentration of the GA
solution. This result indicates that the hardened RBCs do not
change blood ﬂow due to cytoadherence of RBCs in the
microﬂuidic channel. In addition, as shown in Figure 3A-(b),
αBlood is slightly increased at high concentration of GA solution.
Because the deformability of normal RBCs is largely decreased
depending on the concentration of GA solution, viscosity of the
blood sample composed of hardened RBCs increases, which
causes an increase in the blood-ﬁlled width (αBlood).
Then, as a preliminary demonstration for feasible diagnosis
of Pf-infected RBCs with low parasitemia, blood samples
partially mixed with normal and hardened RBCs were prepared
to quantify the variations in RBC deformability and viscosity
caused by small changes in subpopulations of RBCs. The
hardened RBCs were prepared with GA solution of 0.25%. The
hematocrit of the hardened blood sample is adjusted to 50% by
adding hardened RBCs into 1× PBS solution. To evaluate the
performance of the proposed method, heterogeneous blood
samples with diﬀerent hardened blood volume fractions (ψ)
[(a) ψ = 0%, (b) ψ = 2%, (c) ψ = 5%, and (d) ψ = 10%] were
prepared by partially adding normal blood sample into the
hardened blood sample. The volume faction (ψ) is deﬁned as
the volume ratio of the hardened blood sample to the total
blood sample (i.e., ψ = VHardened Blood/VTotal Blood). In this
demonstration, the ﬂow rates of blood sample and reference
ﬂuid were supplied into the microﬂuidic device (LDAC = 250
μm) at the same ﬂow rate of 1 mL/h (i.e., QBlood = QRef = 1
mL/h).
Figure 4. Quantitative performance evaluation for blood samples composed of enhanced RBC aggregation by adding Dextran solution. RBC
aggregation was enhanced by adding diﬀerent concentrations of Dextran solution (CDextran) ranging from CDextran = 0 mg/mL to CDextran = 15 mg/mL
into normal RBCs in PBS suspension (i.e., control blood sample). (A) Variations of ΔVDAC and ΔVBRG with respect to CDextran. (B) Variations of
αBlood with respect to CDextran. Inset shows variations of RBCs-depleted regions in the vertically installed syringe for each concentration of Dextran
solution after ﬁnishing the experiments. (C) Temporal variations of image intensity (<I>) in a speciﬁc region of interest (ROI) in the upper region
of the DAC.
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The temporal variations in ﬂow rate of blood sample
delivered into the DAC (QDAC) with respect to the hardened
blood volume fraction (ψ) [(a) ψ = 0%, (b) ψ = 2%, and (c) ψ
= 10%] are shown in Figure 3B-(a). The results showed that
the ﬂow rate of blood sample supplied into the DAC (QDAC)
dramatically decreased with increasing hardened blood volume
fraction. Successive clogging of RBCs in the microﬂuidic ﬁlter,
which contributed to increasing ﬂuidic resistance in the DAC,
was signiﬁcantly enhanced at high values of the hardened blood
volume fraction. Thus, the ﬂow rate of blood sample delivered
into the DAC decreased with increasing hardened blood
volume fraction. The ﬂow rate supplied into the DAC nearly
stopped within 200 s. After the blood ﬂow stopped, all of the
blood samples ﬂowed into the right lower side channel.
Therefore, variations in blood viscosity were directly quantiﬁed
using eq 1. The blood sample and reference ﬂuid were supplied
into the right lower side channel as parallel ﬂow at the same
ﬂow rate of QBlood = QRef = 1 mL/h.
As shown in Figure 3B-(b), the temporal variations in the
blood-ﬁlled width (αBlood) for two diﬀerent blood samples [(a)
ψ = 0, and (b) ψ = 10%] were quantitatively compared. Blood-
ﬁlled width (αBlood) was remained constant after 200 s. In
addition, αBlood of the hardened blood sample (ψ = 10%) was
distinctively higher than that of the normal blood sample (ψ =
0%). This ﬁnding indicates that blood viscosity of the hardened
blood sample is higher than that of the normal blood sample.
To quantify the variations in blood viscosity, the average value
of αBlood was obtained using several data (n = 100) after 200 s
Using the temporal variations in QDAC as shown in Figure
3B-(a) and eq 4, blood volume delivered into the DAC
(ΔVDAC) was quantiﬁed with respect to the hardened blood
volume fraction (ψ). As depicted in Figure 3B-(c), ΔVDAC
decreased with increasing hardened blood volume fraction. In
addition, the heterogeneous blood sample with ψ = 2% showed
distinctly diﬀerent values of ΔVDAC compared with normal
blood sample (ψ = 0%). Thus, the blood volume delivered into
the DAC (ΔVDAC) could be suitably considered as a
deformability index. In addition, ΔVBRG was slightly decreased
after ψ = 2. In other words, ΔVBRG was decreased because
ﬂuidic resistance (or ﬂuid viscosity) was increased depending
on the hardened volume fraction (ψ). The blood viscosity was
evaluated by monitoring the blood-ﬁlled width (αBlood) with
respect to the hardened blood volume fraction (ψ). As shown
in Figure 3B-(d), αBlood did not show noticeable variation up to
ψ = 5%. However, αBlood of heterogeneous blood sample with ψ
= 10% was higher than that of normal blood sample. From this
result, the blood volume supplied into the DAC (ΔVDAC) was
more eﬀective than the blood-ﬁlled width (αBlood) in the
accurate detection of subpopulations in heterogeneous blood
samples (ψ < 5%).
Detection of Enhanced Aggregation of RBCs. Alter-
nation of blood ﬂow due to enhanced aggregation of RBCs was
evaluated by using the proposed method. RBC aggregation was
gradually enhanced by adding normal RBCs into diﬀerent
concentrations of Dextran solution (CDextran) (MW = 70 kDa,
Sigma-Aldrich, U.S.A.) which ranges from CDextran = 0 mg/mL
to CDextran = 15 mg/mL. As shown in Figure 4A, the ΔVDAC and
ΔVBRG are gradually decreased with increasing the concen-
trations of Dextran solution. In addition, the blood-ﬁlled width
(αBlood) is increased with increasing concentration of the
Dextran solution as depicted in Figure 4B. Previous study on
erythrocyte sedimentation rate (ESR) measurement reported
that Dextran solution increases ESR in a driving syringe.6 The
RBCs-depleted region is expanded from the top with increasing
concentration of Dextran solution. Inset of Figure 4B shows
variations of RBCs-depleted region in a driving syringe after
completing experiments. Since blood sample was supplied from
the bottom position of the syringe into a microﬂuidic device,
hematocrit of the blood sample supplied into the microﬂuidic
device is increased with increasing concentration of Dextran
solution. Thus, the blood-ﬁlled width (αBlood) is increased,
because blood viscosity is proportional to αBlood. In addition,
the enhanced blood viscosity contributes to increasing ﬂuidic
resistance in the microﬂuidic channel. Therefore, the velocity of
blood ﬂow (<U>DAC, <U>BRG) and the supplied blood volume
(ΔVDAC, ΔVBRG) are decreased with increasing concentration
of Dextran solution. Since shear rate is estimated to be 4.1 ×
105 s−1, blood ﬂow behaves as Newtonian ﬂuid. At a high shear
rate, blood ﬂow is strongly inﬂuenced by deformability of
RBCs. Thus, the enhanced aggregation of RBCs does not
change blood ﬂow in the microﬂuidic channel noticeably.
On the other hand, microscopic images of Figure 4C show
dynamic behaviors of RBC aggregation, depending on blood
ﬂow condition in the DAC [(a) before closing the outlet (A),
(b) short-time elapsed after closing the outlet (A), and (c)
long-time elapsed after closing the outlet (A)]. After closing the
outlet (A), blood ﬂow in the DAC is stopped immediately.
Thereafter, RBCs tends to be aggregated or clustered in the
upper region of the DAC. Blood sample added with
concentration of Dextran solution (CGA = 10 mg/mL) exhibits
higher RBC aggregation, compared with normal RBCs in PBS
suspension (i.e., control blood sample). To quantify dynamic
behavior of RBC aggregation in the upper region of DAC, the
average value of image intensity (<I>) in a speciﬁc ROI (475 ×
50 pixels) was estimated using commercial software (Matlab,
Mathworks, U.S.A.). As a result, the enhanced RBC aggregation
induces diﬀerent dynamic behaviors, compared with the control
blood sample. In other words, the image intensity (<I>) of
control blood sample is gradually increased with increasing
elapse of time. However, <I> of the blood sample mixed with
Dextran solution is saturated in a short time. According to
previous study,6 RBC aggregation was quantiﬁed by obtaining a
time constant from temporal variations of the image intensity.
Taking into account the fact that blood sample mixed with
Dextran solution has much smaller time constant than the
control blood sample, Dextran solution contributes to
increasing RBC aggregation positively.
These experimental results indicate that blood sample with
highly aggregated RBCs has little inﬂuence on change of blood
ﬂow due to cytoadherence in the bridge channel. In addition,
the proposed method has a strong potential for evaluating RBC
aggregation of blood sample.
Detection of Pf-Infected RBCs. As a clinical trial, the
proposed method was directly applied to detect blood samples
with Pf-infected RBCs. The average velocities of blood ﬂow
(<U>BRG, <U>DAC), the delivered blood volumes (ΔVDAC,
ΔVBRG), and the blood-ﬁlled width (αBlood) are quantitatively
evaluated with increasing parasitemia and progressing malaria-
infection stage from the ring to the schizont. In this clinical
demonstration, the ﬂow rates of the Pf-infected blood sample
and reference ﬂuid were supplied into the microﬂuidic device
(LDAC = 250 μm) at the same ﬂow rate of QBlood = QRef = 1 mL/
h. The hematocrit of the Pf-infected blood was adjusted to 50%
by adding Pf-infected RBCs into 1× PBS. Each experiment was
repeated three times (n = 3).
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First, using blood samples composed of ring-stage Pf-infected
RBCs, the average velocities in the DAC and bridge channel
(<U>DAC, <U>BRG) were evaluated using a time-resolved micro-
PIV technique. Figure 5A-(a) shows temporal variations of
<U>BRG with respect to parasitemia (P) [(a) P = 0.0005 ±
0.0001%, (b) P = 0.0052 ± 0.0006%, (c) P = 0.0515 ±
0.0064%, and (d) P = 0.515 ± 0.0635%]. For a blood sample
composed of Pf-infected RBCs with parasitemia of 0.515%,
<U>BRG exhibits distinctly unstable variations. In other words,
after a certain period of time, the blood ﬂow in the bridge
channel stops and runs repeatedly. Due to continuous supply of
blood ﬂow by a syringe pump, hydrostatic pressure is gradually
increased in the microﬂuidic channel. Thus, blood leakage
occurs at the inlet (A) as shown in inset of Figure 5A-(a).
Although the <U>BRG of the blood sample composed of RBCs
with parasitemia ranging from 0.0052% to 0.0515% shows
slightly unstable ﬂow behavior, blood leakage does not occur at
the inlet (A) during delivery of blood ﬂow. In addition, the
blood sample composed of Pf-infected RBCs with parasitemia
less than 0.0004% exhibits stable ﬂuidic motions. Figure 5A-(b)
shows temporal variations of αBlood with respect to parasitemia.
The αBlood of the blood sample composed of Pf-infected RBCs
with parasitemia of 0.515% has unstable ﬂuctuations with elapse
of time. To quantify the deformability of blood sample
composed of Pf-infected RBCs, variations of ΔVDAC were
examined with varying parasitemia. As shown in Figure 5A-(c),
ΔVDAC is largely decreased with increasing parasitemia. Because
it is diﬃcult for Pf-infected RBCs to pass through the
microﬂuidic ﬁlters, ΔVDAC tends to decrease with increasing
parasitemia. Inset of Figure 5A-(c) shows microscopic images
of ring-stage Pf-infected RBCs. In addition, the ΔVBRG of Pf-
infected RBCs with parasitemia of 0.515% is signiﬁcantly
Figure 5. Clinical demonstration of the proposed method for the detection of Pf-infected RBCs. The delivered blood volume (ΔVDAC, ΔVBRG),
blood-ﬁlled width (αBlood), and blood velocity (<U>BRG) were quantitatively evaluated, with increasing parasitemia and progressing malaria-infection
stage from the ring to the schizont. Here, the hematocrit of the blood sample with Pf-infected RBCs was ﬁxed at 50%. (A) Detection of ring-stage Pf-
infected RBCs. (a) Temporal variations of <U>BRG with respect to parasitemia (P) [(a) P = 0.0005 ± 0.0001%, (b) P = 0.0052 ± 0.0006%, (c) P =
0.0515 ± 0.0064%, and (d) P = 0.515 ± 0.0635%]. (b) Temporal variations of αBlood with respect to parasitemia. (c) Temporal variations of ΔVDAC
and ΔVBRG with respect to parasitemia. (B) Detection of trophozoite-stage Pf-infected RBCs. (a) Temporal variations of <U>BRG with respect to
parasitemia (P) [(a) P = 0.0005 ± 0.0001%, (b) P = 0.0054 ± 0.001%, (c) P = 0.0544 ± 0.0095%, and (d) P = 0.544 ± 0.095%]. (b) Temporal
variations of αBlood with respect to parasitemia. (c) Temporal variations of ΔVDAC and ΔVBRG with respect to parasitemia. (C) Detection of schizont-
stage Pf-infected RBCs. (a) Temporal variations of <U>BRG with respect to parasitemia (P) [(a) P = 0.0005 ± 0.0001%, (b) P = 0.0054 ± 0.0005%,
(c) P = 0.0538 ± 0.0047%, and (d) P = 0.538 ± 0.0466%]. (b) Temporal variations of αBlood with respect to parasitemia. (c) Temporal variations of
ΔVDAC and ΔVBRG with respect to parasitemia. (D) At a ﬁxed hematocrit of Hct = 5%, <U>BRG, <U>DAC, ΔVDAC, and ΔVBRG for quantitatively
evaluated values of the normal and Pf-infected blood samples were compared. (a) Sequential microscopic images for the normal and Pf-infected
blood samples with respect to elapse of time. (b) Temporal variations of <U>BRG and <U>DAC with respect to parasitemia (P) [(a) P = 0, and (b) P
= 1.9%]. (c) Variations of ΔVDAC and ΔVBRG with respect to parasitemia.
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decreased due to presence of unstable blood ﬂows in the
microﬂuidic channel. This experimental result supports that the
proposed method is capable of detecting ring-stage Pf-infected
RBCs with high parasitemia larger than 0.515%, by monitoring
ﬂow velocity of blood sample, delivered blood volume, blood-
ﬁlled width, and port leakage.
Second, using blood samples composed of trophozoite-stage
Pf-infected RBCs, the average velocities in the DAC and bridge
channel were evaluated. Figure 5B-(a) shows temporal
variations of <U>BRG with respect to parasitemia (P) [(a) P
= 0.0005 ± 0.0001%, (b) P = 0.0054 ± 0.001%, (c) P = 0.0544
± 0.0095%, and (d) P = 0.544 ± 0.095%]. As shown in Figures
5B-(a) and 5B-(b), for a blood sample composed of Pf-infected
RBCs with parasitemia larger than 0.0544%, <U>BRG and αBlood
exhibit signiﬁcantly unstable variations. In addition, blood
leakage occurs at the inlet (A) as shown in Figure S1
(Supporting Information). As depicted in Figure 5B-(c), the
delivered blood volumes (ΔVDAC and ΔVBRG) are largely
decreased with increasing parasitemia. This experimental result
indicates that the proposed method can detect trophozoite-
stage Pf-infected RBCs with parasitemia larger than 0.0544% by
monitoring various parameters handled in this study.
Third, using blood sample composed of schizont-stage Pf-
infected RBCs, the average velocities in the DAC and bridge
channel were evaluated. Figure 5C-(a) shows temporal
variations of <U>BRG with respect to parasitemia (P) [(a) P
= 0.0005 ± 0.0001%, (b) P = 0.0054 ± 0.0005%, (c) P =
0.0538 ± 0.0047%, and (d) P = 0.538 ± 0.0466%]. As shown in
Figures 5C-(a) and 5C-(b), for a blood sample composed of Pf-
infected RBCs with parasitemia larger than 0.0054%, <U>BRG
and αBlood exhibit signiﬁcantly unstable variations. In addition,
blood leakage occurs at the inlet (A) as shown in Figure S1
(Supporting Information). As depicted in Figure 5B-(c),
ΔVDAC and ΔVBRG are signiﬁcantly decreased with increasing
parasitemia. This experimental result supports that the
proposed method has ability to detect schizont-stage Pf-
infected RBCs with parasitemia larger than 0.0054%.
However, the reason for unstable ﬂuidic behaviors of malaria-
infected blood samples in the microﬂuidic channel remains
unknown. According to a previous study,14 the cytoadherence
of Pf-infected RBCs to the surface caused unstable ﬂuidic
behavior. Thus, to observe the cytoadherence of Pf-infected
RBCs speciﬁcally in the microﬂuidic channel, the hematocrit of
malaria-infected blood sample (parasitemia = 1.9%) largely
decreased to 5%. As shown in Figure 5D-(a), microscopic
images were sequentially captured and compared for the
normal and malaria-infected blood samples. Pf-infected RBCs
exhibited remarkable cytoadherence to the microﬂuidic
channel, which hindered blood ﬂow in the microﬂuidic
channels compared with normal blood sample. Using a time-
resolved micro-PIV technique, the temporal variations in
<U>BRG and <U>DAC were measured for the normal and
malaria-infected blood samples. As shown in Figure 5D-(b),
<U>BRG of the malaria-infected blood samples showed unstable
variations compared with normal blood samples. <U>DAC of the
malaria-infected blood sample became zero within approx-
imately 60 s. As shown in the inset of Figure 5D-(b), blood
leakage occurred at the inlet (A). However, <U>DAC of the
normal blood sample continuously decreased in the DAC
channel for 400 s. Using the temporal variations in <U>DAC and
eq 4, the blood volumes delivered into the DAC (ΔVDAC) for
normal and malaria-infected blood samples were compared. As
shown in Figure 5D-(c), ΔVDAC of the malaria-infected blood
sample was much lower than that of the normal blood sample.
In addition, ΔVBRG of the malaria-infected blood sample is
much smaller than that of the normal blood sample, because Pf-
infected RBCs hinders blood ﬂow in the microﬂuidic channels,
compared with normal RBCs.
On the basis of these demonstrations, the proposed method
could be used to detect Pf-infected RBCs eﬀectively by
monitoring average velocity of blood ﬂow (<U>BRG, <U>DAC),
delivered blood volume (ΔVDAC, ΔVBRG), blood-ﬁlled width
(αBlood), and port leakage with good accuracy. However, this
proposed method has a practical limitation on POCT (Point-
Of-Care-Test) or clinical setting. In other words, the
microﬂuidic device can be only used in a laboratory
environment equipped with a microscope. Thus, in resource-
scare clinical environments, the microscope should be replaced
by an analytical sensor which can detect temporal variations of
blood ﬂows in the microﬂuidic device. As a future research
work, various analytical techniques, including pressure sensor,
ﬂow-rate sensor, vibrational spectroscopy,18 and electrode-
based impedance analyzer, will be considered to eﬀectively
detect malaria-infected RBCs.
■ CONCLUSION
Simultaneous quantiﬁcation of biophysical properties of blood
samples was proposed to detect Pf-infected RBCs by measuring
the velocity ﬁelds of blood ﬂow in a microﬂuidic device. The
microﬂuidic device was mimicked from a Wheatstone-bridge
electric circuit. To measure RBC deformability eﬀectively, the
left lower side channel was designed to have a DAC with
parallel microﬂuidic ﬁlters (N = 43, gap = 2 μm, and overall
length = 400 μm). After supplying blood sample and 1× PBS
solution at the same ﬂow rate of QBlood = QPBS = 1 mL/h, the
hemodynamic variations in the microﬂuidic channels were
quantiﬁed using a time-resolved micro-PIV technique. Based on
experimental investigations, blood ﬂow in the DAC stopped
because of successive clogging of RBCs in the microﬂuidic
ﬁlters, especially within 200 s. Thus, the blood volume
delivered into the DAC (ΔVDAC) for 200 s was suggested as
a deformability index. Thereafter, using parallel ﬂows in a single
channel of the microﬂuidic device, the viscosity ratio of blood
sample to the reference ﬂuid was quantiﬁed by monitoring
blood-ﬁlled width (αBlood). Furthermore, the blood volume
delivered into the bridge channel (ΔVBRG) for 100 s was
suggested as a cytoadherence index. Thus, the deformability,
viscosity, and cytoadherence of blood samples that were
determined from hemodynamic variations in the microﬂuidic
channel were used to detect Pf-infected RBCs in a label-free
and high-throughput manner.
The eﬀects of four factors, namely, the length of microﬂuidic
ﬁlter (LDAC), blood ﬂow rate (QBlood), hematocrit (Hct), and
base solution, were experimentally evaluated. On the basis of
the results, the hematocrit of blood sample was ﬁxed at 50%,
and the length of the microﬂuidic ﬁlter in the DAC was set at
250 μm.
Homogeneous hardened blood sample and heterogeneous
blood samples partially mixed with normal and hardened RBCs
were prepared to evaluate variations in RBC deformability and
viscosity caused by small variations in subpopulations of RBCs.
The blood volume supplied into the DAC (ΔVDAC) was more
eﬀective than the blood-ﬁlled width (αBlood) in detecting
heterogeneous blood samples with hardened blood volume
fraction (ψ) (ψ < 5%).
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Blood sample composed of RBCs with enhanced aggregation
was evaluated by employing the proposed method. RBC
aggregation was gradually enhanced by adding normal RBCs
into Dextran solution. Blood sample with highly aggregated
RBCs has little inﬂuence on the change of blood ﬂow in the
bridge channel. Furthermore, RBC aggregation of blood sample
was evaluated by monitoring temporal variations of image
intensity (<I>) in the DAC, after closing the outlet (A).
As a clinical demonstration, the proposed method was
applied to detect blood samples composed of Pf-infected RBCs.
When parasitemia was greater than 0.515% for ring stage,
0.0544% for trophozoite stage, and 0.0054% for schizont stage,
average velocity of blood ﬂow and blood-ﬁlled width showed
unstable ﬂuctuations. After a certain period, the blood ﬂow
stopped and ran repeatedly. Finally, the blood leakage occurred
in the inlet (A). This unstable ﬂuidic behavior was checked by
monitoring the cytoadherence of Pf-infected RBCs to the
surface of the microﬂuidic channel. ΔVDAC as a deformability
index and ΔVBRG as cytoadherence index signiﬁcantly decreased
with increasing parasitemia.
These results indicated that the proposed method could be
used to detect Pf-infected RBCs by monitoring average
velocities of blood ﬂow (<U>BRG, <U>DAC), delivered blood
volumes (ΔVDAC, ΔVBRG), blood-ﬁlled width (αBlood), and port
leakage with good accuracy. Furthermore, the experimental
procedures for a blood sample of 0.2 mL with a high hematocrit
level of 50% were completed within a short time period (∼5
min). The proposed method will be tested further to evaluate
the blood biophysical properties of blood samples related to
various hematological diseases.
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